# Dominantly Inherited Alzheimer Network: Imaging Core

> **NIH NIH U19** · WASHINGTON UNIVERSITY · 2022 · $953,097

## Abstract

Core G: Imaging Summary
The imaging data set collected in the Dominantly Inherited Alzheimer Network (DIAN) participants to date
represents a highly valuable resource for Alzheimer's disease (AD) research. It has supported cross sectional
analysis of PET and MRI data to develop a timeline for imaging biomarkers in autosomal dominant AD
(ADAD). With this renewal application, the DIAN Imaging Core will continue to obtain and analyze longitudinal
imaging data that is fully integrated with clinical, psychometric and cerebrospinal fluid (CSF) biomarkers, and
will allow for mutation-specific genotype-phenotype analysis.
Imaging Core will be responsible for the acquisition, quality control, and analysis of the MRI and PET
neuroimaging for DIAN. Carriers of AD-causing mutations and their non-carrier siblings are enrolled and
followed in the Clinical Core through the international DIAN performance sites. Participants will undergo
structural and functional MRI, amyloid PET, tau PET, and metabolic PET imaging every 2 years, in conjunction
with their clinical visits. The source imaging data and post-processed data will be available to collaborating and
outside investigators and will be distributed by the Informatics and Biostatistics cores.
For tau PET, we will now obtain scans with the tracers [18F]-MK-6240, [18F]-AV-1451 (aka Flortaucipir, T807),
and [18F]-PI-2620. Because no single tracer has the international distribution to reach all sites, each site is
assigned one for the three tau PET tracers. Using multiple tracers maximizes the number of DIAN sites that
can perform tau PET imaging. Including multiple tracers across the study diminishes the risk of choosing one
tracer for such a large, international study of unique participants. Approximately 1/3 of participants will undergo
imaging with each tracer. We recognize the limitations of using multiple tracers in the same study and have
taken steps to minimize this risk. Based upon our preliminary work, each tracer is independently powered to
detect significant effects (see Project 2, Approach). Further, our current proposal is adaptive. If our
immunohistochemistry and autoradiographic work (Project 2) demonstrates that one candidate tracer is
unsuitable (i.e. THK-5351 binding to monoamine oxidase B44), it will be replaced with another. Over the course
of the proposal we will also work with Pharma partners to strengthen tracer availability to a wider international
network.

## Key facts

- **NIH application ID:** 10462562
- **Project number:** 5U19AG032438-11
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Tammie Lee Smith Benzinger
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $953,097
- **Award type:** 5
- **Project period:** 2008-09-15 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10462562

## Citation

> US National Institutes of Health, RePORTER application 10462562, Dominantly Inherited Alzheimer Network: Imaging Core (5U19AG032438-11). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10462562. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*